/https://covers.openlibrary.org/b/id/606622-L.jpg)
Her-2
by
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later …
- ● 91% match for you
the long version
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer free. This is the biography of Her-2, Herceptin, the drug that provoked dramatic responses in Barbara and other women in the trials that offers promise for hundreds of thousands of women.
Margaret's verdict
"Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in …"
highlights
what readers held onto
No highlights yet. Be the first.
discussion
what readers said
No reviews yet. Finish it; tell us what you found.